Podcast Episodes
Back to Search
Analysts Thursdays: Clear Street Senior Biotech Analyst Kaveri Pohlman shares her take on biotech for 2026 and discusses her top picks
She discusses Arrivent Biopharma, Oruka Therapeutics, Jade Biosciences, Zura Bio, and Pavella Therapeutics.
7 months, 3 weeks ago
SF Healthcare Week: Perceptive Advisors' Joe Edelman, one of the top investors in biotech, shares his investment philosophy and his take on the sector heading into 2026
He talks about Perceptive's investment philosophy, his take on the year ahead, areas he thinks are over and under hyped, and thoughts on China. Plus,…
7 months, 4 weeks ago
SF Healthcare Week: Cytokinetics CEO Robert Blum discusses the approval and impending launch of the cardiomyopathy therapy MYQORZO
He discussed the REMS, launch plans, market opportunity, payors, and the metrics that the company will offer publicly over time. Plus, previewing a k…
8 months ago
SF Healthcare Week: Sana Bio's CEO Steve Harr describes the science behind the company's cell therapy program that aims to be a cure for type 1 diabetes
He describes one patient data from an investigator led study in Europe, and explains how Sana's program is slighly different. The company aims to fil…
8 months ago
SF Healthcare Week: Alumis' CEO Martin Babler walks us through the two successful phase 3 trials the company announced for its TYK2 last week
He discusses the TYK2 landscape and describes why Alumis believes TYK2 can be a broad class in immunology.
8 months ago
SF Healthcare Week: CEO Heather Turner tells us about the neuropsychiatric diseases medicine that enabled LB Pharma to IPO in a tough market last year
She walks us through LB-102, a methylated derivative of amisulpride, a therapy that has a history of success in Europe. Plus, her thoughts on the obe…
8 months ago
SF Healthcare Week: Neurocrine Biosciences CEO Kyle Gano describes how the company's novel muscarinic agonist portfolio is rooted in novel drug design, with its lead M4 agonist in late-stage trials
Plus, how the neuroscience company has used its long history working with corticotropin releasing factor to move into obesity, with a project that ac…
8 months ago
SF Healthcare Week: Recursion's new CEO Najat Khan shares her vision for the company and for AI in biotech
Najat Khan describes the impact Recursion's work is having, such the surprising PoC of using MEK1/2 inhibition as a target for treating Familial Aden…
8 months ago
SF Healthcare Week: Wave Life Sciences CEO Paul Bolno discusses the company's INHBE obesity program, AATD, PNPLA3, and more
He describes the 'best-in-class' profile he believes INHBE can show in the obesity space. Plus the latest on other programs and how Wave is working o…
8 months ago
SF Healthcare Week: Roivant CEO Matt Gline provides an update on the 'vant ecosystem
He discusses key data in the year ahead including from Immunovant and Priovant. Plus, an update on the lawsuits regarding covid vaccine LNP delivery …
8 months ago